Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Cannabinoid receptor 2 (CB2) & Pain

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

In spite of the interest of targeting CB2r for pain, clinical trials evaluating CB2r agonist analgesic efficacy have currently failed.
Cabañero et al. 2021 Expert Opinion on Therapeutic Targets, 25: 659-676

The preferential involvement of CB2r in preventing the development of chronic pain could influence the failure of clinical trials designed for the treatment of already established pain syndromes.
Cabañero et al. 2021 Expert Opinion on Therapeutic Targets, 25: 659-676

References (Sources)

The CB2 cannabinoid receptor as a therapeutic target in the central nervous system
Cabañero et al. 2021 Expert Opinion on Therapeutic Targets, 25: 659-676
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Cannabinoid receptor 2 (CB2) & Pain

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat